Galmed Pharmaceuticals (EOCN) Research & Development (2013 - 2026)
Galmed Pharmaceuticals' Research & Development was $1.78 million in Q2 2026, up 68.4% from $1.06 million a year earlier and up 31.0% from the prior quarter.
Powered by 
Analysis
Galmed Pharmaceuticals (EOCN) Research & Development (2013 - 2026) Analysis & Trends
On a trailing twelve-month basis, Galmed Pharmaceuticals' Research & Development was $2.51 million through Jun 30, 2026, up 21.9% year-over-year; for FY2025, it was $1.06 million, down 31.1% from FY2024.
- Research & Development has now declined for four consecutive years, with a five-year compound annual growth rate of -47.3% (FY2020 to FY2025).
- In earlier years, Research & Development was $1.54 million in FY2024 (-57.0%), $3.57 million in FY2023 (-72.5%), $13 million in FY2022 (-52.3%) and $27.22 million in FY2021 (+4.4%).
- The Q2 2026 figure marks the highest quarterly Research & Development since Q3 2022.
- Compared with a year earlier, Research & Development was higher in five of the last six quarters, with growth averaging 60.1%.
- The best year-over-year quarter for Research & Development over five years was Q1 2026 (growth of 114.5%); the worst was Q3 2023 (a decline of 86.9%).
- Per Business Quant data, EOCN's Research & Development in the three quarters before Q2 2026 was $1.36 million (Q1 2026), -$1.72 million (Q4 2025) and $1.09 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,130.22 Bn | 1,098.81 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 613.62 Bn | 532.15 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 501.46 Bn | 474.57 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 366.84 Bn | 321.22 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.85 Bn | 261.84 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 235.39 Bn | 190.79 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 169.57 Bn | 116.22 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Galmed Pharmaceuticals | 1.60 Mn | -39.09 Mn | - | 1.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.78 Mn |
| Mar 31, 2026 | 1.36 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | 634,000.00 |
| Dec 31, 2024 | 1.07 Mn |
| Sep 30, 2024 | 738,000.00 |
| Jun 30, 2024 | 534,000.00 |
| Mar 31, 2024 | 635,000.00 |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 556,000.00 |
| Jun 30, 2023 | 809,000.00 |
| Mar 31, 2023 | 1.08 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 4.24 Mn |
| Jun 30, 2022 | 2.58 Mn |
| Mar 31, 2022 | -170,000.00 |
| Dec 31, 2021 | 6.26 Mn |
| Sep 30, 2021 | 6.54 Mn |
API Access
Galmed Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=EOCN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "EOCN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=EOCN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();